A Study Assessing KB407 for the Treatment of Cystic Fibrosis

NCTID	NCT05504837 (View at clinicaltrials.gov)
Description	This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis. (Show More)
Indication	Cystic Fibrosis
Compound Name	KB-407
Sponsor	Krystal Biotech, Inc.
Funder Type	Industry
Status	Recruiting
Enrollment Count	12

Target Gene/Variant	CFTR
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Functional gene replacement
Route of Administration	Inhalational
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	HSV-1
Editor Type
Dose 1	Undisclosed dose (single administration)
Dose 2	Undisclosed dose (2 administrations)
Dose 3	Undisclosed dose (4 administrations)
Dose 4
Dose 5

No.of Trial Sites	2
Locations	United States

Has US IND	True
Recent Updates	Completed dosing in first two cohorts and on track to start third in Q2 2024